Navigation Links
Chewable Tablet Might Offer New Help for Diabetes Patients

MANCHESTER, N.H., Jan. 8, 2014 /PRNewswire/ -- Among those with Type 2 diabetes, the body either resists the effects of insulin, or the pancreas doesn't produce enough insulin to maintain a normal glucose level. What if these patients implemented a healthier diet and regular exercise?

According to R. Paul Robertson, M.D., president, Medicine and Science, of the American Diabetes Association, diabetes can be made to go into remission, but it will always be there. But, he says, patients can make significant strides against the disease, often to the point of quitting medication. The good news is that for some people who have lost weight, kept blood sugar levels stable, eat right and work out, doctors may allow them to go off their medications. 

As researchers strive for improved treatment options, the best one can do right now is to eat right, exercise and watch for complications. Oh, and one more thing: watch for PAZ320. Currently being developed by Boston Therapeutics, Inc., a Manchester, NH-based pharmaceutical company, PAZ320 is a non-systemic, non-toxic chewable drug candidate that is designed to inhibit enzymes that release glucose from complex carbohydrates in foods during digestion. In a Phase IIa study last year, 45 percent of Type 2 diabetes patients taking metformin responded to PAZ320 with a 40 percent reduction of post-meal glucose in the blood. 

David Platt, Ph.D., Boston Therapeutics' CEO, explains that they set out to make one molecule that would block enzymes that participate in the digestion of sugar. The resulting polysaccharide—a new class of drugs called carbohydrate hydrolyzing enzyme inhibitors (CHEI)—is taken before meals, working in the gastrointestinal tract to "disable" the carbs. In other words, it blocks the action of carbohydrate-hydrolyzing enzymes that break carbohydrates down into glucose.

As they wait for new treatments, Type 2 diabetes patients might one day benefit from this chewable "disabler."

For more, visit, who paid for the writing and dissemination of this release.

Contact:  Laura Radocaj, Dian Griesel Int'l.  212.825.3210

SOURCE Boston Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
3. Mylan Launches Generic Version of Plavix® Tablets
4. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
5. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
6. Mylan Launches Generic Version of Viramune® Tablets
7. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
8. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
9. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
10. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
11. Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is jam-packed ... the palates of attendees is of the utmost importance. Whether you are cooking ... give these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless ... treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, ... without the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro ...
(Date:11/25/2015)... ... 25, 2015 , ... According to an article published November 10th ... widely heralded as a breakthrough for performing hernia repairs. The article explains that the ... is that it can greatly reduce the pain that a patient might otherwise experience ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... physicians and athletic programs, launches new Wimbledon Athletics Facebook page to ... young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
Breaking Medicine News(10 mins):